Dux Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-07-2024
- Paid Up Capital ₹ 0.10 M
as on 09-07-2024
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 174.99%
(FY 2020)
- Profit 37.61%
(FY 2020)
- Ebitda 172.48%
(FY 2020)
- Net Worth -64.56%
(FY 2020)
- Total Assets 20.19%
(FY 2020)
About Dux Remedies
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Kumar and Monika Sharma serve as directors at the Company.
- CIN/LLPIN
U74900UP2011PTC043353
- Company No.
043353
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jan 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Bareilly, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Dux Remedies Private Limited offer?
Dux Remedies Private Limited offers a wide range of products and services, including Vitamin Tablets & Capsules, Vitamin C Tablets & Capsules, Pain Reliever Gel, Combiflam Gel, Pain Relief Drugs & Pharmaceuticals, Pain Relief Spray, Antipyretic Medication, Disprin Tablet, Combiflam Pain Relief Spray.
Who are the key members and board of directors at Dux Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Kumar  | Director | 29-Mar-2023 | Current |
| Monika Sharma | Director | 29-Mar-2023 | Current |
Financial Performance of Dux Remedies.
Dux Remedies Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 174.99% increase. The company also saw a substantial improvement in profitability, with a 37.61% increase in profit. The company's net worth observed a substantial decline by a decrease of 64.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dux Remedies?
Unlock access to Dux Remedies's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dux Remedies?
Unlock and access historical data on people associated with Dux Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dux Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dux Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
